A 26-year-old man comes to the clinic seeking treatment for opioid use disorder. He has been injecting heroin daily for the past three years. The patient states, "I am tired of living like this and want to start the medication that stops cravings." He reports his last heroin use was two hours ago. Currently, he appears comfortable and cooperative. Vital signs are temperature 37.0°C (98.6°F), blood pressure 118/76 mm Hg, pulse 72/min, and respiratory rate 14/min. Physical examination reveals pinpoint pupils and track marks on bilateral antecubital fossae. The physician discusses initiating buprenorphine-naloxone therapy. Arrange the following steps for initiating this therapy in the correct chronological order from first to last.
- 1Instruct the patient to abstain from short-acting opioids for at least 12-24 hours.
- 2Assess for objective signs of mild-to-moderate withdrawal using a standardized clinical scale.
- 3Administer the initial induction dose of sublingual buprenorphine-naloxone.
- 4Titrate the medication dosage over several hours based on the suppression of withdrawal symptoms.
- 5Establish a stable maintenance dose and integrate ongoing psychosocial counseling.
Cevap
The correct sequence is to first have the patient abstain from opioids for 12-24 hours, then objectively assess for mild-to-moderate withdrawal, administer the initial dose of buprenorphine, titrate the dosage based on symptom relief, and finally establish a maintenance dose with psychosocial counseling.
Buprenorphine is a partial mu-opioid agonist with a remarkably high affinity for the receptor. If administered while a full agonist (such as heroin) is still occupying the receptors, buprenorphine will aggressively displace the full agonist. Because it only partially activates the receptor, this sudden displacement leads to a rapid drop in overall opioid receptor stimulation, precipitating severe withdrawal symptoms. Therefore, the critical first steps in induction are instructing the patient to abstain from short-acting opioids for at least 12-24 hours, and then objectively verifying that they are in mild-to-moderate withdrawal (often utilizing the COWS scale). Only after objective withdrawal is confirmed can the initial dose be safely administered. Afterward, the dose is titrated, and the patient is transitioned to long-term maintenance therapy paired with psychosocial support.
Adım Adım Çözüm
Anahtar Kavram
Buprenorphine induction requires patients to be in mild-to-moderate withdrawal prior to the first dose to prevent precipitated opioid withdrawal.
Tahmini Süre:1m 30s